Gilead Sciences News

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. announced today that the company will be webcasting its corporate presentation at two upcoming investor conferences: the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, California.

Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019 http://www.reportlinker.com/p0869191/Hepatitis-B-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy GlobalData, the industry analysis specialist, has released its new report, "Hepatitis B ... (more)

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. announced today that the Marketing Authorisation Application for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency .

Gilead Sciences Inc. is an innovative healthcare company with a strong record of historical earnings growth and expectations for above-average growth into the future.

This week, the U.S. Food and Drug Administration will consider allowing an anti-HIV drug to be promoted to otherwise healthy, HIV-free people as a purely preventative measure for the first time.

Truvada, a once-daily antiretroviral pill, is effective for preventing sexual transmission of HIV and should be approved as post-exposure prophylaxis, or PrEP, a Food and Drug Administration advisory committee voted last week.

New York-based Hedge Fund Baker Bros. Advisors LLC, as of the most recent SEC 13-F Q1 filing , had $3.7 billion in equity assets, almost all invested in the biotech sector, and an increase from the $3.0 billion in Q4 and $2.3 billion in Q3 of 2011.

Netflix, Inc. : Needham believes that increases in Netflix's domestic streaming margins will be largely offset by a decline in higher margin DVD subscription revenues.

NEW YORK, May 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials , and Nanodevices/Tools. The report provides separate comprehensive analytics for the ... (more)

Citing "enhanced prospects for new drug approvals and a favorable outlook for mergers and acquisitions," S&P Capital IQ extolled the virtues of investing in the biotechnology sector and highlighted several ETFs offering exposure to biotech stocks in a new research note.

In trading on Monday, the Biotech ETF is outperforming other ETFs, up about 0.5% on the day.

Gilead Sciences Inc. 's experimental HIV pill Quad, the new medicine from the world's largest maker of AIDS drugs, gained a U.S. advisory panel's backing to treat patients infected with the virus.

Gilead Sciences , the Foster City-based pharmaceutical giant, is counting on a groundbreaking HIV-prevention drug to bolster its future earnings.

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection ... (more)

Gilead Sciences Inc. won the backing of an advisory panel for the first approval of a drug to prevent HIV infections in healthy people.

This photo provided by Gilead Sciences shows Truvada. A panel of federal health advisers votes today, Thursday, May 10, 2012, on whether to endorse the first drug shown to prevent HIV infection, potentially clearing the way for a landmark approval in the 30-year effort against the virus that causes AIDS.

SILVER SPRING, Md. -- The first drug shown to prevent HIV infection won the endorsement of a panel of federal advisers Thursday, clearing the way for a landmark approval in the 30-year fight against the virus that causes AIDS.

Plus, the gloves are off as GlaxoSmithKline has mounted a hostile offer for its long-time partner Human Genome Sciences.

US health advisors are poised to decide Thursday on whether to recommend the drug, Truvada, as the first preventive pill against AIDS instead of just a treatment for infected people.

U.S. Food and Drug Administration would support the use of Truvada , HIV drug by Gilead Sciences Inc.